These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 27939305)
1. Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function. Rondinelli M; Rossi A; Gandolfi A; Saponaro F; Bucciarelli L; Adda G; Molinari C; Montefusco L; Specchia C; Chiara Rossi M; Scardapane M; Arosio M; Genovese S Clin Ther; 2017 Jan; 39(1):159-169. PubMed ID: 27939305 [TBL] [Abstract][Full Text] [Related]
2. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486 [TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness and safety of liraglutide in clinical practice. Ponzani P Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446 [TBL] [Abstract][Full Text] [Related]
4. Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort. Mirani M; Favacchio G; Serone E; Lucisano G; Rossi MC; Berra CC Pharmacol Res; 2018 Nov; 137():270-279. PubMed ID: 30213563 [TBL] [Abstract][Full Text] [Related]
5. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis. McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289 [TBL] [Abstract][Full Text] [Related]
7. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Kuhadiya ND; Malik R; Bellini NJ; Patterson JL; Traina A; Makdissi A; Dandona P Endocr Pract; 2013; 19(6):963-7. PubMed ID: 23807520 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of liraglutide after three years of treatment. Ponzani P; Scardapane M; Nicolucci A; Rossi MC Minerva Endocrinol; 2016 Mar; 41(1):35-42. PubMed ID: 26878560 [TBL] [Abstract][Full Text] [Related]
9. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes. Wijkman MO; Dena M; Dahlqvist S; Sofizadeh S; Hirsch I; Tuomilehto J; Mårtensson J; Torffvit O; Imberg H; Saeed A; Lind M J Clin Hypertens (Greenwich); 2019 Jan; 21(1):105-115. PubMed ID: 30515978 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. Lapolla A; Berra C; Boemi M; Bossi AC; Candido R; Di Cianni G; Frontoni S; Genovese S; Ponzani P; Provenzano V; Russo GT; Sciangula L; Simioni N; Bette C; Nicolucci A; Adv Ther; 2018 Feb; 35(2):243-253. PubMed ID: 29270781 [TBL] [Abstract][Full Text] [Related]
11. Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting. Di Dalmazi G; Coluzzi S; Baldassarre MPA; Sorbo SE; Dell'Aquila S; Febo F; Ginestra F; Graziano G; Rossi MC; Consoli A; Formoso G Clin Ther; 2020 Sep; 42(9):1738-1749.e1. PubMed ID: 32753164 [TBL] [Abstract][Full Text] [Related]
12. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Montvida O; Klein K; Kumar S; Khunti K; Paul SK Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433 [TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis. Chang KC; Shao SC; Kuo S; Yang CY; Chen HY; Chan YY; Ou HT Cardiovasc Diabetol; 2020 Oct; 19(1):172. PubMed ID: 33036617 [TBL] [Abstract][Full Text] [Related]
14. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy. Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047 [TBL] [Abstract][Full Text] [Related]
15. Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study. Hiramatsu T; Ozeki A; Ishikawa H; Furuta S Drug Res (Stuttg); 2017 Nov; 67(11):640-646. PubMed ID: 28738426 [No Abstract] [Full Text] [Related]
16. The effect of liraglutide on renal function: A randomized clinical trial. von Scholten BJ; Persson F; Rosenlund S; Hovind P; Faber J; Hansen TW; Rossing P Diabetes Obes Metab; 2017 Feb; 19(2):239-247. PubMed ID: 27753201 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study. Gautier JF; Martinez L; Penfornis A; Eschwège E; Charpentier G; Huret B; Madani S; Gourdy P Adv Ther; 2015 Sep; 32(9):838-53. PubMed ID: 26424330 [TBL] [Abstract][Full Text] [Related]
18. Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting. Simioni N; Berra C; Boemi M; Bossi AC; Candido R; Di Cianni G; Frontoni S; Genovese S; Ponzani P; Provenzano V; Russo GT; Sciangula L; Lapolla A; Bette C; Rossi MC; Acta Diabetol; 2018 Jun; 55(6):557-568. PubMed ID: 29527621 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Li CJ; Li J; Zhang QM; Lv L; Chen R; Lv CF; Yu P; Yu DM Cardiovasc Diabetol; 2012 Nov; 11():142. PubMed ID: 23153177 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]